TRANSLATE

The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more
 Charles Mullighan

Charles Mullighan

Co-Chair

Charles G. Mullighan is a member of the Department of Pathology, deputy director at the Comprehensive Cancer Center, and co-leader of the Hematological Malignancies Program at St. Jude Children’s Research Hospital, Memphis, US. He is also the medical director at St. Jude Biorepository. Charles received his training in medicine, hematology, and hematopathology in Adelaide, AU, and undertook doctoral studies in immunogenetics at the University of Oxford, UK. His research interests include the use of integrated genomic and epigenomic approaches to understand the pathogenesis and evolution of ALL and related disorders; defining the interaction of inherited and somatic genetic alterations in leukemogenesis; the use of in vitro and in vivo experimental approaches to model genomic abnormalities in leukemogenesis; and preclinical therapeutic testing to translate genomic discoveries to new treatment approaches in ALL.

Filter by content: